Codexis (CDXS) to Release Earnings on Thursday

Codexis (NASDAQ:CDXS) is expected to be announcing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $18.5150 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Codexis had a negative net margin of 113.67% and a negative return on equity of 105.83%. The company had revenue of $15.33 million during the quarter, compared to the consensus estimate of $14.18 million. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Stock Performance

Shares of Codexis stock opened at $2.56 on Thursday. The company has a 50 day moving average of $2.60 and a 200-day moving average of $2.54. Codexis has a 1-year low of $1.90 and a 1-year high of $6.08. The company has a current ratio of 5.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.71. The company has a market cap of $231.09 million, a PE ratio of -3.08 and a beta of 2.50.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CDXS shares. Wall Street Zen raised shares of Codexis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Codexis in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Codexis has an average rating of “Hold” and an average price target of $11.00.

Hedge Funds Weigh In On Codexis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Opaleye Management Inc. lifted its stake in Codexis by 32.6% in the 2nd quarter. Opaleye Management Inc. now owns 12,600,000 shares of the biotechnology company’s stock valued at $30,744,000 after purchasing an additional 3,100,000 shares during the last quarter. Nantahala Capital Management LLC lifted its stake in Codexis by 42.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,030,619 shares of the biotechnology company’s stock valued at $9,835,000 after purchasing an additional 1,200,000 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Codexis by 0.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,550,806 shares of the biotechnology company’s stock valued at $6,224,000 after purchasing an additional 16,099 shares during the last quarter. Geode Capital Management LLC lifted its stake in Codexis by 2.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,977,869 shares of the biotechnology company’s stock valued at $4,827,000 after purchasing an additional 52,588 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in Codexis by 24.9% in the 1st quarter. Royal Bank of Canada now owns 437,126 shares of the biotechnology company’s stock valued at $1,176,000 after purchasing an additional 87,044 shares during the last quarter. Institutional investors own 78.54% of the company’s stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.